TY  - GEN
AU  - Rubinstein,Maria M
AU  - Hyman,David M
AU  - Caird,Imogen
AU  - Won,Helen
AU  - Soldan,Krysten
AU  - Seier,Kenneth
AU  - Iasonos,Alexia
AU  - Tew,William P
AU  - O'Cearbhaill,Roisin E
AU  - Grisham,Rachel N
AU  - Hensley,Martee L
AU  - Troso-Sandoval,Tiffany
AU  - Sabbatini,Paul
AU  - Guillen,Joyce
AU  - Selcuklu,S Duygu
AU  - Zimel,Catherine
AU  - Torrisi,Jean
AU  - Aghajanian,Carol
AU  - Makker,Vicky
TI  - Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
SN  - 1097-0142
PY  - 2020///1009
KW  - Aged
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Class Ia Phosphatidylinositol 3-Kinase
KW  - genetics
KW  - Endometrial Neoplasms
KW  - drug therapy
KW  - Enzyme Activation
KW  - Female
KW  - Humans
KW  - Hyperglycemia
KW  - chemically induced
KW  - Hypoalbuminemia
KW  - Hypophosphatemia
KW  - Middle Aged
KW  - Mutation
KW  - PTEN Phosphohydrolase
KW  - Phosphatidylinositol 3-Kinases
KW  - Progression-Free Survival
KW  - Proto-Oncogene Proteins c-akt
KW  - Pyridines
KW  - adverse effects
KW  - Quinolones
KW  - Signal Transduction
KW  - TOR Serine-Threonine Kinases
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1002/cncr.32677
ER  -